Sign up
Pharma Capital

Callitas Health expects to roll out 'ToConcieve' product in the fourth quarter

Callitas Health (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) CEO James Thompson tells Proactive Investors that the clinical-stage pharmaceutical company is working through the R&D phase to get its ToConceive product onto retail shelves by the fourth quarter.

In March, Callitas announced a partnership with NFI Consumer Healthcare, the maker of pregnancy test kit e.p.t. to package the company's fertility lubricant. Callitas expects to see revenue from NFI in the second half of this year.


View full LILY profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.